AT101

AT101 is a CAR-T cell therapy developed by AbClon. Its target is CD19 (the sponsor names CD19). The sponsor states: Autologous chimeric antigen receptor (CAR) T cells engineered to recognise CD19 on B-cell non-Hodgkin lymphoma cells. ClinicalTrials.gov describes the intervention as: Anti-CD19 Chimeric Antigen Receptor T cell. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT05338931, plans to enrol 82 participants with primary completion expected 2030-03-15. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.